Riversedge Advisors LLC Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)

Riversedge Advisors LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 11.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,943 shares of the company’s stock after purchasing an additional 396 shares during the period. Riversedge Advisors LLC’s holdings in Johnson & Johnson were worth $618,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of JNJ. Blackston Financial Advisory Group LLC bought a new position in Johnson & Johnson in the fourth quarter worth about $463,000. Red Door Wealth Management LLC raised its stake in Johnson & Johnson by 5.8% in the fourth quarter. Red Door Wealth Management LLC now owns 46,401 shares of the company’s stock worth $7,273,000 after buying an additional 2,552 shares in the last quarter. Dash Acquisitions Inc. raised its stake in Johnson & Johnson by 15.7% in the fourth quarter. Dash Acquisitions Inc. now owns 1,930 shares of the company’s stock worth $312,000 after buying an additional 262 shares in the last quarter. Sage Financial Management Group Inc. raised its stake in Johnson & Johnson by 31.8% in the fourth quarter. Sage Financial Management Group Inc. now owns 2,934 shares of the company’s stock worth $460,000 after buying an additional 708 shares in the last quarter. Finally, First PREMIER Bank increased its stake in shares of Johnson & Johnson by 0.6% during the fourth quarter. First PREMIER Bank now owns 45,651 shares of the company’s stock valued at $7,155,000 after purchasing an additional 278 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 1.4 %

Shares of JNJ stock opened at $157.96 on Thursday. Johnson & Johnson has a 12-month low of $144.95 and a 12-month high of $175.97. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. The firm’s 50 day moving average is $158.76 and its 200 day moving average is $156.69. The stock has a market capitalization of $380.65 billion, a P/E ratio of 11.44, a P/E/G ratio of 2.62 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. The company had revenue of $21.40 billion for the quarter, compared to analysts’ expectations of $21.02 billion. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. Johnson & Johnson’s revenue for the quarter was down 9.7% compared to the same quarter last year. During the same period last year, the firm earned $2.35 EPS. Research analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th were given a $1.19 dividend. The ex-dividend date of this dividend was Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.01%. Johnson & Johnson’s payout ratio is currently 34.47%.

Insider Activity

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of analyst reports. UBS Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their target price for the company from $167.00 to $180.00 in a research note on Friday, December 1st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 28th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Raymond James raised their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, March 13th. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $177.31.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.